Recombinant antibodies (rAbs) are monoclonal antibodies that are generated in vitro using synthetic genes while monoclonal antibodies (mAbs) are produced using traditional hybridoma-based technologies, the immunovirology and vaccine laboratory houses hi-tech equipment for generation of both antibodies.These antibodies are effective therapeutic treatments for different immune disorders and diseases.The capacity to develop large quantities of well-characterized monoclonal antibody preparations advanced diagnostic and therapeutic medicine. The use ofrAbs plays an important role in the development and production of renewable supplies of low-cost reagents for diagnostic and therapeutic applications.
Since this technology involves the rapid cloning of immunoglobulin gene segments to create immune libraries from which antibodies with desired specificities can be selected NiiN uses state-of-the-art antibody technologies to isolate natural disease-fighting antibodies directly from virus-infected patient blood samples and employs antibody discovery/engineering technologies.